Xenon Pharmaceuticals
XENE
38 hedge funds and large institutions have $40.3M invested in Xenon Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
23% more funds holding
Funds holding: 31 → 38 (+7)
2.48% less ownership
Funds ownership: 58.65% → 56.17% (-2.5%)
50% less capital invested
Capital invested by funds: $80.8M → $40.3M (-$40.5M)
62% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 13
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.46M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$2.68M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.33M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$1.6M |
| 5 |
AG
Artal Group
Luxembourg
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.87M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.75M |
| 3 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$2.45M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.49M |
| 5 |
Millennium Management
New York
|
-$1.49M |
XENE Hedge Fund Activity: Q1 2017 in Review
38 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2017, worth a combined $40.3M — down 50% from $80.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new XENE positions and 4 closed out — a net gain of 7 holders — while 5 added to existing stakes and 13 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $3.46M. The largest seller was OrbiMed, cutting an estimated $2.87M.
- 38 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2017, up from 31 in Q4 2016.
- Funds reported $40.3M of Xenon Pharmaceuticals stock for Q1 2017, down 50% quarter-over-quarter.
- 11 funds opened new Xenon Pharmaceuticals positions in Q1 2017 and 4 closed out, a net change of +7 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2017 was Alyeska Investment Group, an estimated $3.46M added.
- The largest Xenon Pharmaceuticals seller in Q1 2017 was OrbiMed, an estimated $2.87M sold.
Based on aggregated 13F filings for Q1 2017.